Results 141 to 150 of about 37,560 (339)

andererseits - Yearbook of Transatlantic German Studies [PDF]

, 2018
William Donahue, Tobias Boes, Jens Gurr, Suzanne Marchand, Tanja Nusser, Thomas Pfau, Mark Roche, Denise Rossa, Carsten Dutt, Steffen Kaupp, Achim Kpper, Mary Henrichs, Thomas Kpper, Margarethe Von Trotta, Ma- Rion Poschmann, Sowie Klaus, Georg Mein, Tom Kummer, Mit Einem Vorwort, Ulf Poschardt, Zack Von Der Fremden Freiheit, Marie Eberhardt, Clemens Mit, Meyer, Uta Mathes, Mit Lukas, Antje Vowinckel, Heinz Hirschenhuber, Michael Bachmann, Friedrich Knilli, Wiederaufbaus, Jahren, Traumtanz, Ein, Klaus Lesebuch, Bernhard Modick, Lassahn, Rez, Robert Karl, Mandelkow, Klaus Modick, ; Ins Blaue, Roman, Ulrich Baron, ; Klaus Modick, ;, Guy Helminger, Norbert Scheuer, Terzia Mora, Kathrin Rggla, Marion Poschmann Und Vielen, Von George Aus Fhren Viele Wege Nach Amerika, Eckhart Grnewald, ; Stefan, Georges Briefe, D Amslinger, Julia, Marie-Luise ; Eberhardt, D Erb, D Henderson, Heike, Hannes Krauss, D De Lieber, Laura, D Oh, -Jae ; Seung, Palberg, D Profit, Vera   +68 more
openalex   +1 more source

Reviewers for the 2023 IMIA Yearbook of Medical Informatics [PDF]

, 2023
Boyd Andrew, Cornet Ronald, Cossin Sbastien, France Karen, Canada Christel, Elkin Peter, Ellis Louise, Estiri Australia, Jesualdo Hossein, Toms, , , , , , , , , , , , , , , , ,   +26 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Timely: Gorman, G E, and Rowland, F, edsScholarly publishing in an electronic era.International yearbook of library and information management 2004/2005. London: Facet Publishing, 2004. 240p £60.00 hard ISBN 1856045366 (available from James Bennett Pty Ltd) [PDF]

, 2005
Toby Burrows
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Yearbook on International Communist Affairs, 1968. Edited by Richard V. Allen. Stanford: Hoover Institution Press, 1969. xvii, 1,165 pp. $25.00. [PDF]

, 1970
Bernard S. Morris
openalex   +1 more source

Visual Interpretations, Cartoons, and Caricatures of Student and Youth Cultures in University Yearbooks, 1898–1930

, 2008
E. L. Panayotidis, Paul J. Stortz
semanticscholar   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Supplements to the Yearbooks of Major Japanese Newspapers as a Source for Onomastic Research

, 2021
Evgenia L. Frolova
openalex   +1 more source